Actualités Alvontech - ALVO | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the...

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the...

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the...

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the...

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global...

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global...

Main Results of 2026 Annual and Extraordinary General Meeting

REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary...

Alvotech to present at upcoming investor conferences in June

REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a...

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026...

Alvotech Q1 2026 Financial Results

REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM:...

Alvotech Announces a Change in its Executive Team

REYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global...

Alvotech to Report Financial Results for the First Quarter of 2026

REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a...

Alvotech Files Annual Report with the SEC

REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its...

Alvotech Q4 2025 and Full Year 2025 Financial Results

REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM:...

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alvontech (ALVO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Alvontech (ALVO) Actualités

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Main Results of 2026 Annual and Extraordinary General Meeting

Alvotech to present at upcoming investor conferences in June

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Q1 2026 Financial Results

Alvotech Announces a Change in its Executive Team

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech Files Annual Report with the SEC

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alvontech (ALVO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Alvontech (ALVO) Actualités

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Main Results of 2026 Annual and Extraordinary General Meeting

Alvotech to present at upcoming investor conferences in June

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Alvotech Q1 2026 Financial Results

Alvotech Announces a Change in its Executive Team

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech Files Annual Report with the SEC

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités